{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T01:46:26Z","timestamp":1783734386556,"version":"3.55.0"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T00:00:00Z","timestamp":1652918400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2022,6]]},"abstract":"<jats:sec>\n            <jats:title>BACKGROUND<\/jats:title>\n            <jats:p>The use of esthetic products by millennials is increasing, yet published clinical trial data in this population are limited.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVE<\/jats:title>\n            <jats:p>To compare the efficacy and safety of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in millennial and nonmillennial patients.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>METHODS AND MATERIALS:<\/jats:title>\n            <jats:p>Post hoc analyses were performed on the pooled population of all patients treated with 20U prabotulinumtoxinA in the 3 single-dose Phase III glabellar line clinical studies. Patients were grouped by age: millennials (born 1982\u20132000) versus nonmillennials (born \u22641981). One key efficacy end point was the proportion of responders with a \u22651-point improvement from baseline at maximum frown on the 4-point Glabellar Line Scale. Adverse events were also summarized.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS<\/jats:title>\n            <jats:p>Responder rates among millennials (<jats:italic toggle=\"yes\">n<\/jats:italic> = 65) were greater than those of nonmillennials (<jats:italic toggle=\"yes\">n<\/jats:italic> = 668) by 7.7% on average across all visits; differences were statistically significant at Day 90. Responder rates at Day 90 were 90.2% and 76.1%, respectively (absolute difference of 14.0%, <jats:italic toggle=\"yes\">p<\/jats:italic> = .01). Headache was the most common treatment-related adverse event, occurring in 9.0% and 9.4% of millennials and nonmillennials, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSION<\/jats:title>\n            <jats:p>A single dose of 20U prabotulinumtoxinA administered for the treatment of glabellar lines was similarly well-tolerated by both millennials and nonmillennials; overall, it was more efficacious in millennials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/dss.0000000000003456","type":"journal-article","created":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T11:00:49Z","timestamp":1653562849000},"page":"664-669","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["PrabotulinumtoxinA for Treatment of Millennials With Moderate to Severe Glabellar Lines: Post Hoc Analyses of the Phase III Clinical Study Data"],"prefix":"10.1097","volume":"48","author":[{"given":"Patricia","family":"Ogilvie","sequence":"first","affiliation":[{"name":"Dermatologist, SkinConcept, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek H.","family":"Jones","sequence":"additional","affiliation":[{"name":"Skin Care and Laser Physicians of Beverly Hills, Los Angeles, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui L.","family":"Avelar","sequence":"additional","affiliation":[{"name":"Evolus, Inc., Newport Beach, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneke","family":"Jonker","sequence":"additional","affiliation":[{"name":"Medical Writing Associates, West Vancouver, British Columbia, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rose","family":"Monroe","sequence":"additional","affiliation":[{"name":"Evolus, Inc., Newport Beach, California;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Carruthers","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,19]]},"reference":[{"key":"R5-20250731","first-page":"1340","article-title":"The millennial mindset","volume":"17","author":"Sherber","year":"2018","journal-title":"J Drugs Dermatol"},{"key":"R6-20250731","first-page":"62","article-title":"Making sense of millennials","volume":"10","author":"Seery","year":"2016","journal-title":"Mod Aesthetics"},{"issue":"Suppl 1","key":"R8-20250731","first-page":"1","article-title":"The Aesthetic Society's cosmetic surgery national data bank: statistics 2019","volume":"40","year":"2020","journal-title":"Aesthet Surg J"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"3210","DOI":"10.1111\/jocd.13768","article-title":"Growth of cosmetic procedures in millennials: a 4.5-year clinical review","volume":"19","author":"Wang","year":"2020","journal-title":"J Cosmet Dermatol"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"100","DOI":"10.36849\/JDD.2020.4641","article-title":"Minimally invasive facial cosmetic procedures for the millennial aesthetic patient","volume":"19","author":"Mobayed","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"R14-20250731","first-page":"1","article-title":"\u201cMillennial botulinum toxin\u201d: a retrospective age-matched cohort study with onabotulinumtoxinA","volume":"10","author":"Chung","year":"2021","journal-title":"Dermatol Surg"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1097\/DSS.0000000000001903","article-title":"Efficacy and safety of prabotulinumtoxinA for the treatment of glabellar lines in adult subjects: results from 2 identical phase III studies","volume":"45","author":"Beer","year":"2019","journal-title":"Dermatol Surg"},{"key":"R16-20250731","first-page":"413","article-title":"A multicenter, randomized, double-blind, placebo-controlled, single-dose, Phase III, non-inferiority study comparing prabotulinumtoxinA and onabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult subjects","volume":"40","author":"Rzany","year":"2020","journal-title":"Aesthet Surg J"},{"key":"R17-20250731","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/asj\/sjaa383","article-title":"The first of two 1-year, multicenter, open-label, repeat-dose, Phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients","volume":"41","author":"Kaufman-Janette","year":"2021","journal-title":"Aesthet Surg J"},{"key":"R18-20250731","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1093\/asj\/sjaa382","article-title":"The second of two 1-year, multicenter, open-label, repeat-dose, Phase II safety studies of prabotulinumtoxinA for the treatment of moderate to severe glabellar lines in adult patients","volume":"41","author":"Lorenc","year":"2021","journal-title":"Aesthet Surg J"},{"key":"R19-20250731","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1007\/s00266-020-01983-w","article-title":"A review of complications due to the use of botulinum toxin A for cosmetic indications","volume":"45","author":"Sethi","year":"2021","journal-title":"Aesth Plast Surg"},{"key":"R20-20250731","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/DSS.0000000000002216","article-title":"Efficacy, patient-reported outcomes, and safety for millennial subjects treated with onabotulinumtoxinA for moderate to severe horizontal forehead lines","volume":"46","author":"Palm","year":"2020","journal-title":"Dermatol Surg"},{"issue":"Suppl 1","key":"R21-20250731","first-page":"s5","article-title":"Re-examining the optimal use of neuromodulators and the changing landscape: a consensus panel update","volume":"19","author":"Kaminer","year":"2020","journal-title":"J Drugs Dermatol"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003456","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T22:06:51Z","timestamp":1753999611000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DSS.0000000000003456"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,19]]},"references-count":13,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000003456","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,19]]}}}